Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Chimeric Antibody Market Size And Revenue Outlook Through 2030
The chimeric antibody market has experienced swift expansion recently. This market is projected to expand from $13.74 billion in 2025 to $15.36 billion in 2026, registering a compound annual growth rate (CAGR) of 11.8%. Historically, this growth was driven by the initial achievements of monoclonal antibody treatments, dependence on murine antibody innovations, a rise in cancer cases, the increasing occurrence of autoimmune diseases, and broader immunological research efforts.
The chimeric antibody market is projected for substantial expansion in the coming years. It is anticipated to reach $23.73 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.5%. This growth during the forecast period is attributable to several factors, including progress in antibody engineering methods, a rise in biologic drug approvals, the widening scope of personalized medicine, increased investment in biopharmaceutical research and development, and an expanding clinical pipeline for chimeric antibodies. Key trends foreseen for this period encompass the growing integration of chimeric antibodies into oncology treatments, their expanding application in managing autoimmune and inflammatory conditions, increasing demand for highly specific monoclonal antibody therapies, the broadening application of recombinant DNA and phage display technologies, and their enhanced safety profile alongside reduced immunogenicity when compared to murine antibodies.
Get A Free Sample Report With In-Depth Market Insights:
Chimeric Antibody Market Development Factors: What’s Supporting Demand?
The rising incidence of cancer is anticipated to fuel the expansion of the chimeric antibody market in the future. Cancer prevalence signifies the overall count of individuals, including both recent and prior diagnoses, who are currently living with a history of the disease at a given moment. This increase in cancer prevalence is linked to lifestyle factors like unhealthy eating habits, smoking, excessive alcohol intake, and exposure to environmental contaminants, all of which heighten the likelihood of developing different types of cancer. Chimeric antibodies improve cancer treatment approaches by providing targeted therapies, enabling their effectiveness against particular tumor cells. These antibodies minimize adverse effects through precise attacks on malignant cells, thereby enhancing patient results and the effectiveness of treatment. As an illustration, in October 2025, data from the National Health Service (NHS), a government health agency in the UK, indicated 354,820 new cancer diagnoses in 2023, averaging 972 daily, which represented an increase of 8,605 compared to 2022. Consequently, the expanding prevalence of cancer is a key factor propelling the growth of the chimeric antibody market.
Chimeric Antibody Market Segment Analysis Spotlighting Growth Areas
The chimeric antibody market covered in this report is segmented –
1) By Type Of Antibody: Immunoglobulin G Chimeric Antibodies, Fragment Antigen-Binding Chimeric Antibodies, Single-Chain Variable Fragment Chimeric Antibodies
2) By Manufacturing Process: Recombinant Deoxyribonucleic Acid (DNA) Technology, Hybridoma Technology, Phage Display Technology
3) By Mode Of Administration: Intravenous (IV) Administration, Subcutaneous Administration, Intramuscular Administration
4) By Application: Cancer Therapy, Autoimmune Diseases, Infectious Diseases, Transplant Rejection
5) By End User: Pharmaceutical Companies, Research Institutes, Clinics And Hospitals
Subsegments:
1) By Immunoglobulin G Chimeric Antibodies: Full Length Immunoglobulin G (IgG), Engineered Immunoglobulin G 1 (IgG1), Engineered Immunoglobulin G4 (IgG4)
2) By Fragment Antigen-Binding Chimeric Antibodies: Bivalent Fragment Antigen-Binding (Fab) Fragments, Monovalent Fragment Antigen-Binding (Fab) Fragments, Conjugated Fragment Antigen-Binding (Fab) Fragments, Pegylated Fragment Antigen-Binding (Fab) Fragments
3) By Single-Chain Variable Fragment Chimeric Antibodies: Standard Single-Chain Fragment Variable, Tandem Single-Chain Fragment Variable, Bispecific Single-Chain Fragment Variable, Multivalent Single-Chain Fragment Variable
Chimeric Antibody Market Transformation Trends: What Innovations Are Driving Change?
Major companies operating in the chimeric antibody market are increasingly concentrating on advanced therapeutic approaches, such as monoclonal antibodies, to enhance treatment outcomes, improve patient survival rates, and address critical medical conditions. Monoclonal antibodies are laboratory-engineered proteins that emulate the immune system’s natural ability to combat harmful pathogens, including viruses and inflammatory agents. For instance, in June 2023, InflaRx N.V., a Germany-based biopharmaceutical company, commercially launched Gohibic (vilobelimab). This is a chimeric monoclonal antibody designed to target C5a in the complement system, thereby blocking C5a-mediated immune responses to alleviate excessive inflammation, and is utilized for the treatment of COVID-19 in hospitalized adults when administered within 48 hours of initiating invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). This innovative therapy represents a considerable advancement in addressing hyperinflammation in severe infections, offering an additional treatment option for high-risk patients.
Chimeric Antibody Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the chimeric antibody market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Merck KGaA, BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc.
View The Full Chimeric Antibody Market Report:
Chimeric Antibody Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the chimeric antibody market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chimeric antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model